Stockreport

AbbVie Announces Extension of Review for Supplemental New Drug Application of Upadacitinib for the Treatment of Moderate to Severe Atopic Dermatitis

AbbVie Inc.  (ABBV) 
Last abbvie inc. earnings: 5/1 07:43 am Check Earnings Report
US:NYSE Investor Relations: investors.abbvie.com/investor-overview
PDF NORTH CHICAGO, Ill., April 2, 2021 /PRNewswire/ -- AbbVie (NYSE:ABBV), a global research and development-based biopharmaceutical company, announced that the U.S. Food an [Read more]